A Phase 2 interventional study of PRX-08066 in Pulmonary Hypertension and Chronic Obstructive Pulmonary Disease, sponsored by Epix Pharmaceuticals, Inc.. Completed at 19 sites in United States. Open to participants aged 25 Years to 79 Years. Per ClinicalTrials.gov, last updated 2008-05-29.
Sponsored by Epix Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment
This study is being conducted to see if PRX-08066 can lower pulmonary artery pressures in patients with pulmonary hypertension associated with chronic obstructive pulmonary disease.
3,303 studies on the registry are indexed under Lung Diseases; 355 are open to participants now.
This study's planned enrollment of 72 is close to the median of 72 across 2,118 interventional studies indexed under Lung Diseases.
Browse Lung Diseases studies →Epix Pharmaceuticals, Inc. is the lead sponsor of 7 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Systolic Pulmonary Artery Pressure
Safety
6 minute walk distance
Borg Dyspnea Index
BDI/TDI
Echocardiograms
Spirometry
Oxygen saturation
WHO functional classification
This study is completed, as verified in May 2008. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Epix Pharmaceuticals, Inc.